Esperion Therapeutics (NASDAQ: ESPR)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-02 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.040 | -0.930 | 0.1100 | ||||
REV | 15.390M | 18.836M | 3.446M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Esperion Therapeutics (NASDAQ: ESPR) through any online brokerage.
Other companies in Esperion Therapeutics’s space includes: Atea Pharmaceuticals (NASDAQ:AVIR), GH Research (NASDAQ:GHRS), Aerie Pharmaceuticals (NASDAQ:AERI), WAVE Life Sciences (NASDAQ:WVE) and Verona Pharma (NASDAQ:VRNA).
The latest price target for Esperion Therapeutics (NASDAQ: ESPR) was reported by Goldman Sachs on Tuesday, May 24, 2022. The analyst firm set a price target for 3.00 expecting ESPR to fall to within 12 months (a possible -53.49% downside). 11 analyst firms have reported ratings in the last year.
The stock price for Esperion Therapeutics (NASDAQ: ESPR) is $6.45 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Esperion Therapeutics.
Esperion Therapeutics’s Q2 earnings are confirmed for Tuesday, August 2, 2022.
There is no upcoming split for Esperion Therapeutics.
Esperion Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.